Latest Manufacturing News

Terra Critical Minerals has expanded its True American Tungsten Project in Nevada to over 1,130 acres, revealing new high-grade tungsten mineralisation from surface samples. This under-explored system, untouched since the 1940s, now offers promising dual-style mineralisation targets ahead of a planned spring exploration campaign.

Morella Corporation has expanded its rubidium exploration footprint at the Mt Edon Project in Western Australia, identifying multiple new high-grade targets with assays up to 2.84% Rb2O. This development strengthens the company's position in the critical minerals sector alongside its lithium assets.

1414 Degrees has achieved a key milestone with its SiNTL silicon anode material reaching 500 mAh/g, matching current commercial standards ahead of schedule and setting sights on 600 mAh/g within a year.

Sparc Technologies and the Australian Institute for Machine Learning are developing AI-driven software to transform protective coatings corrosion assessment, promising faster, more accurate results for a global market of testing labs.

Rhythm Biosciences has secured a multi-year commercial manufacturing agreement with US-based Quansys Biosciences to produce ColoSTAT® reagent kits, paving the way for broader market rollout of its colorectal cancer diagnostic test.

5E Advanced Materials is raising up to $36 million through a stock offering to fund the development of its Fort Cady boron and lithium project in California. The capital raise comes amid ongoing concerns about the company’s ability to continue as a going concern without further financing.

Yowie Group has landed a three-year seasonal licence to produce and distribute beloved Australian confectionery brands Violet Crumble, Polly Waffle, and FruChocs across Australia and New Zealand, targeting $6.5 million in net sales.

Actinogen Medical has raised approximately $17 million through a share placement and purchase plan to fund the completion of its pivotal XanaMIA Alzheimer’s trial following encouraging interim results.

PYC Therapeutics has launched a A$653 million capital raising to fund the clinical advancement of four RNA-based drug candidates targeting genetic diseases with significant unmet needs. The raise extends the company’s cash runway to 2030, supporting key clinical milestones and a transition to commercialisation.

F.F.I. Holdings anticipates a modest decline in half-year profit, citing one-off lease expenses despite steady food operations.

CurveBeam AI has received the first A$4 million tranche of a planned A$10 million strategic investment from a leading Chinese orthopaedic device company, marking a significant step in its expansion into the Chinese market.

Imagion Biosystems has submitted its Investigational New Drug application to the U.S. FDA for its MagSense® HER2 Imaging Agent, marking a pivotal step toward launching a Phase 2 clinical trial for breast cancer detection.